Article Details

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Retrieved on: 2024-05-29 11:35:35

Tags for this article:

Click the tags to see associated articles and topics

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis. View article details on hiswai:

Excerpt

... monoclonal antibody in clinical development for multi-organ fibrosis ... Alentis is the leading company pioneering anti-CLDN1 antibodies and ADCs to ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up